retatrutide triple agonist glp-1 gip glucagon phase 2 obesity Retatrutide: The GLP-1/GIP/Glucagon Triple-Agonist Guide to Weight Loss, Appetite Control & Metabolic Reset The Science Behind Retatrutide: A

It helps most patients control their T2DM and causes clinically significant weight loss

doi:10.2337/dc11-s231 Jensterle M, Rizzo M, Haluzk M, Jane A

administration of oxytocin, which inhibits food intake via activation of vagal afferents 27 , exerted its anorexigenic effect in Glp1r KO and WT mice to similar extents (Fig

Chronic kidney disease (CKD) (e.g., FLOW), 3

The Role of Prescribers in Closing the Gap The gap between what the clinical evidence supports and what patients typically receive as guidance when they are prescribed a GLP-1 is, in my experience, significant

Reduced appetite is the intended effect, though it sometimes feels too extreme